Theranostic for metastatic melanoma
This article was originally published in Start Up
SolaranRx Inc. is jumping on the theranostics bandwagon by tackling the deadly skin cancer melanoma, which for advanced cases has a staggering survival rate of only six months and a one-year mortality of 75%. The company’s lead compound, SRX-1177, is a novel peptide linked to a radioisotope that can preferentially attach to melanocortin-1, a unique receptor overexpressed on melanoma cells.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Israeli-based start-up Tyto Care markets TytoHome, a device that allows consumers to check their ears, breathing and temperature from home and share the findings with a clinician for remote diagnosis.
The race continues to heat up in the bioprinting space over which players will first reach the finish line in gaining approval for tissue and organ replacements. Research organizations and companies worldwide are in various states of development for these milestones in regenerative medicine, ranging from bioprinting skin to a mini human heart. But regulatory hurdles and quality testing could be formidable.